Patients with HT who received replacement with levothyroxine (L-T4) did not always achieve clinically significant results, which requires additional therapeutic agents ( The significant prevalence of AITD, a long latent period and the involvement of autoimmune processes in their occurrence, development of concomitant diseases, insufficient effectiveness of the main pharmacotherapy, and a decrease in the quality of life of patients require the development of adequate approaches for the correction of immune processes in order to prevent and treat diseases
Please help me to understand this
Pemov A, Li H, Presley W, Wallace MR, Miller DT
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease
You actually absorb what you swallow
B., Quijada-Rodriguez, A